Physician profile
Ali Sanai
NPI 1689728545
$467.49
in general payments reported to CMS, 2019-2025
9 companies · $13.71 in 2025
The $13.71 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $197 · 2023: $164 · 2024: $92.78 · 2025: $13.71.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $172 · Education: $98.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $171.74 |
| Education | $98.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $141.97 | 2023 | Opsumit, Uptravi |
| Pfizer INC. | $131.84 | 2021 | |
| Boston Scientific Corporation | $92.78 | 2024 | Wavewriter Alpha Prime 16 |
| Glaxosmithkline, LLC. | $22.27 | 2023 | Arexvy, Shingrix |
| Amarin Pharma, INC. | $20.85 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $15.77 | 2021 | |
| Janssen Pharmaceuticals, INC | $14.84 | 2021 | |
| Esperion Therapeutics, INC. | $13.71 | 2025 | Nexletol |
| Teva Pharmaceuticals USA, INC. | $13.46 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Sanai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.